Abstract
Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have